Adaptive Biotechnologies Corp. (ADPT)
28.35
+0.98
(+3.58%)
USD |
NASDAQ |
Oct 02, 16:00
28.34
-0.02
(-0.05%)
After-Hours: 20:00
Adaptive Biotechnologies Cash from Operations (TTM) : -21.01M for June 30, 2026
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | -21.01M |
| March 31, 2026 | -27.04M |
| December 31, 2025 | -45.99M |
| September 30, 2025 | -60.53M |
| June 30, 2025 | -80.47M |
| March 31, 2025 | -85.34M |
| December 31, 2024 | -95.21M |
| September 30, 2024 | -109.65M |
| June 30, 2024 | -129.27M |
| March 31, 2024 | -135.52M |
| December 31, 2023 | -156.32M |
| September 30, 2023 | -159.41M |
| June 30, 2023 | -155.14M |
| March 31, 2023 | -178.64M |
| Date | Value |
|---|---|
| December 31, 2022 | -183.94M |
| September 30, 2022 | -207.75M |
| June 30, 2022 | -208.79M |
| March 31, 2022 | -198.94M |
| December 31, 2021 | -192.73M |
| September 30, 2021 | -178.74M |
| June 30, 2021 | -182.46M |
| March 31, 2021 | -176.32M |
| December 31, 2020 | -149.68M |
| September 30, 2020 | -136.63M |
| June 30, 2020 | -119.61M |
| March 31, 2020 | -104.50M |
| December 31, 2019 | 205.40M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (TTM) Benchmarks
| Personalis, Inc. | -92.30M |
| 10X Genomics, Inc. | 127.08M |
| Alamar Biosciences, Inc. (California) | -56.62M |
| Champions Oncology, Inc. | -5.564M |
| Medpace Holdings, Inc. | 752.66M |